AMOT

Across TCGA pan-cancer cohorts, AMOT Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated AMOT data layer compared with 16 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AMOT Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated AMOT expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, BLCA, and SKCM are the cancer types where AMOT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.951	0.295	.001	36	view →
BLCA	OS	Median	II,III,IV	1.000	0.410	.017	28	view →
SKCM	OS	Median	III,IV	0.335	0.714	.001	17	view →
BRCA	OS	Median	III,IV	0.287	0.833	.002	12	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
CESC	DFS	Median	IV	0.215	0.539	.042	8	view →
PRAD	DFS	Median	All	0.085	0.774	.009	6	view →
HNSC	OS	Median	All	0.271	0.605	.043	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

AMOT–UCEC (DFS)

Open the UCEC breakdown →